Table 3 Summary of the outcome of studies conducted with BM-MNCs
From: Cell therapies for autism spectrum disorder: a systematic review of clinical applications
| Â | Sharma et al. [78] | Bansal et al. [7] | Nguyen Thanh et al. [61] |
|---|---|---|---|
CARS (ISAA) | Improved significantly | Improved | Improved significantly |
CGI-I | Improved significantly | - | - |
CGI-II | 96.9% showed global improvement | - | - |
CGI-III | - 21.9% marked therapeutic effect - 40.6% moderate therapeutic - 28% minimal therapeutic effect | - | - |
FIM, Wee FIM | No change | - | Â |
VAB-II | - | - | Improved significantly |
Social relationship and reciprocity | Improved significantly | - | Improved significantly |
Emotional responsiveness | Improved significantly | - | - |
Speech, language, communication | Improved significantly | - | Improved significantly |
Behavior patterns | Improved significantly | - | Improved significantly |
Sensory aspects | Improved significantly | - | Improved significantly |
Cognitive component | Improved significantly | - | - |
PET-CT | Increased metabolism after cellular transplantation | - | No significant change |
Major adverse events | None | None | None |